Cholinergic treatments for tardive dyskinesia.
D000109:Acetylcholine / Q000378:metabolism; D014150:Antipsychotic Agents / Q000009:adverse effects; D002794:Choline / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003342:Corpus Striatum / Q000378:metabolism; D003642:Deanol / Q000627:therapeutic use; D004298:Dopamine / Q000378:metabolism; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D010277:Parasympathomimetics / Q000627:therapeutic use*; D010713:Phosphatidylcholines / Q000627:therapeutic use; D010830:Physostigmine / Q000627:therapeutic use; D012107:Research Design; D013375:Substance Withdrawal Syndrome
D014150:Antipsychotic Agents; D010277:Parasympathomimetics; D010713:Phosphatidylcholines; D003642:Deanol; D010830:Physostigmine; D002794:Choline; D000109:Acetylcholine; D004298:Dopamine